Patient characteristics included in chimerism analyses
| Characteristic . | Relapse status . | |
|---|---|---|
| No . | Yes . | |
| Numbers, n | 155 | 68 |
| Chimerocyte type of assay run, n (%) | ||
| HLA-specific assay(s) (with or without non-HLA specificities) | 31 (20.0) | 15 (22.1) |
| Non-HLA–specific assay(s) only | 124 (80.0) | 53 (77.9) |
| Age at transplant (y), median (IQR) | 52 [40 - 62] | 52 [39 - 60] |
| Sex, n (%) | ||
| Female | 63 (40.6) | 35 (51.5) |
| Male | 92 (59.4) | 33 (48.5) |
| Ancestral background, n (%) | ||
| Caucasian | 87 (75.0) | 46 (83.6) |
| Asian | 14 (12.1) | 2 (3.6) |
| American Native (including Alaska, Hawaii, and Pacific Islands) | 7 (6.0) | 4 (7.3) |
| Mixed/multiple | 3 (2.6) | 3 (5.5) |
| Sub-Saharan African | 5 (4.3) | 0 (0.0) |
| Unknown/missing data | 39 | 13 |
| Transplant type, n (%) | ||
| Related (haplo or HLA matched) | 15 (9.7) | 16 (23.5) |
| Unrelated cord blood (single or combined) | 57 (36.8) | 15 (22.1) |
| Unrelated (HLA matched or mismatched) | 83 (53.5) | 37 (54.4) |
| Conditioning, n (%) | ||
| TBI 1200-1320; FLU, CY | 40 (25.8) | 14 (20.6) |
| TBI 300-400; CY with or without FLU | 27 (17.4) | 7 (10.3) |
| TBI 200; FLU based (with CY, ATG, RAB, and/or TREO) | 47 (30.3) | 27 (39.7) |
| No TBI; BU based (with CY, FLU, and/or ATG) or FLU based (with either L-PAM or TREO) | 41 (26.5) | 20 (29.4) |
| GVHD prophylaxis, n (%) | ||
| CSP + MMF (with or without RAPA, CY, or FK506) | 88 (56.8) | 22 (32.4) |
| CSP + MTX (with or without CY or FK506) | 8 (5.2) | 6 (8.8) |
| FK506 + MMF (with or without CY or RAPA) | 15 (9.7) | 16 (23.5) |
| FK506 + MTX (with or without steroids or ABA) | 44 (28.4) | 24 (35.3) |
| Diagnosis, n (%) | ||
| ALL | 30 (19.4) | 7 (10.3) |
| AML | 84 (54.2) | 49 (72.1) |
| MDS | 41 (26.5) | 12 (17.6) |
| MRD based on MFC status before transplant, n (%) | ||
| Positive (>0%) | 41 (27.3) | 31 (48.4) |
| Negative (=0%) | 109 (72.7) | 33 (51.6) |
| Missing data | 5 | 4 |
| Disease status at transplant, n (%) | ||
| Active disease | 13 (8.4) | 15 (22.1) |
| CR1 | 70 (45.2) | 28 (41.2) |
| CR2 | 30 (19.4) | 13 (19.1) |
| CR3 | 5 (3.2) | 1 (1.5) |
| Undefined (mostly including patients with MDS) | 37 (23.9) | 11 (16.2) |
| Characteristic . | Relapse status . | |
|---|---|---|
| No . | Yes . | |
| Numbers, n | 155 | 68 |
| Chimerocyte type of assay run, n (%) | ||
| HLA-specific assay(s) (with or without non-HLA specificities) | 31 (20.0) | 15 (22.1) |
| Non-HLA–specific assay(s) only | 124 (80.0) | 53 (77.9) |
| Age at transplant (y), median (IQR) | 52 [40 - 62] | 52 [39 - 60] |
| Sex, n (%) | ||
| Female | 63 (40.6) | 35 (51.5) |
| Male | 92 (59.4) | 33 (48.5) |
| Ancestral background, n (%) | ||
| Caucasian | 87 (75.0) | 46 (83.6) |
| Asian | 14 (12.1) | 2 (3.6) |
| American Native (including Alaska, Hawaii, and Pacific Islands) | 7 (6.0) | 4 (7.3) |
| Mixed/multiple | 3 (2.6) | 3 (5.5) |
| Sub-Saharan African | 5 (4.3) | 0 (0.0) |
| Unknown/missing data | 39 | 13 |
| Transplant type, n (%) | ||
| Related (haplo or HLA matched) | 15 (9.7) | 16 (23.5) |
| Unrelated cord blood (single or combined) | 57 (36.8) | 15 (22.1) |
| Unrelated (HLA matched or mismatched) | 83 (53.5) | 37 (54.4) |
| Conditioning, n (%) | ||
| TBI 1200-1320; FLU, CY | 40 (25.8) | 14 (20.6) |
| TBI 300-400; CY with or without FLU | 27 (17.4) | 7 (10.3) |
| TBI 200; FLU based (with CY, ATG, RAB, and/or TREO) | 47 (30.3) | 27 (39.7) |
| No TBI; BU based (with CY, FLU, and/or ATG) or FLU based (with either L-PAM or TREO) | 41 (26.5) | 20 (29.4) |
| GVHD prophylaxis, n (%) | ||
| CSP + MMF (with or without RAPA, CY, or FK506) | 88 (56.8) | 22 (32.4) |
| CSP + MTX (with or without CY or FK506) | 8 (5.2) | 6 (8.8) |
| FK506 + MMF (with or without CY or RAPA) | 15 (9.7) | 16 (23.5) |
| FK506 + MTX (with or without steroids or ABA) | 44 (28.4) | 24 (35.3) |
| Diagnosis, n (%) | ||
| ALL | 30 (19.4) | 7 (10.3) |
| AML | 84 (54.2) | 49 (72.1) |
| MDS | 41 (26.5) | 12 (17.6) |
| MRD based on MFC status before transplant, n (%) | ||
| Positive (>0%) | 41 (27.3) | 31 (48.4) |
| Negative (=0%) | 109 (72.7) | 33 (51.6) |
| Missing data | 5 | 4 |
| Disease status at transplant, n (%) | ||
| Active disease | 13 (8.4) | 15 (22.1) |
| CR1 | 70 (45.2) | 28 (41.2) |
| CR2 | 30 (19.4) | 13 (19.1) |
| CR3 | 5 (3.2) | 1 (1.5) |
| Undefined (mostly including patients with MDS) | 37 (23.9) | 11 (16.2) |
ABA, abatacept; ATG, antithymocyte globulin; BU, busulfan; CSP, cyclosporine; CR1/2/3, first/second/third complete remission; CY, cyclophosphamide; FK506, tacrolimus; FLU, fludarabine; haplo, haploidentical; IQR, interquartile range; L-PAM, melphalan; MMF, mycophenolate mofetil; RAB, radiolabeled antibodies; RAPA, rapamycin; TBI, total body irradiation (in cGy); TREO, treosulfan.